Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia

  • End date
    Sep 30, 2024
  • participants needed
  • sponsor
    Novartis Pharmaceuticals
Updated on 13 June 2021
Novartis Pharmaceuticals
Primary Contact
Novartis Investigative Site (8.1 mi away) Contact
+12 other location


This study is designed to evaluate the efficacy and safety of eltrombopag when added to r-ATG and CsA in treatment naive East-Asian adult and pediatric patients with SAA.

Condition Severe Aplastic Anemia
Treatment Eltrombopag, Cyclosporine A (CSA), rabbit anti-thymocyte globulin (r-ATG)
Clinical Study IdentifierNCT04328727
SponsorNovartis Pharmaceuticals
Last Modified on13 June 2021


Yes No Not Sure

Inclusion Criteria

Written study informed consent and (where applicable) assent from the subject, parent, or guardian must be obtained prior to participation in the study
Subjects of East Asian ethnicity aged 6 years old at the time of written informed consent and assent form (if applicable)
SAA characterized by
Bone marrow cellularity < 25%, or 25-50% with < 30% residual hematopoietic cells and pancytopenia, with at least two of the following parameters in peripheral blood
Absolute neutrophil count < 0.5109/L
Platelet count < 20109/L
Absolute reticulocyte count < 20109/L
HSCT is not suitable or available as a treatment option (determined as per local practices or national guidelines), or has been refused by subject

Exclusion Criteria

Prior IST with any ATG/ALG , alemtuzumab, high dose cyclophosphamide ( 45 mg/kg/day), CsA within 6 months, or prior thrombopoietin receptor agonists
Eastern Cooperative Oncology Group (ECOG) performance status (age 16 years) >2, or Lansky performance status (age < 16 years) <50\
Prior and/or active medical history of
Known underlying congenital/inherited bone marrow failure or aplastic anemia (e.g.,such as but not limited to Fanconi anemia, congenital dyskeratosis, congenital amegakaryocytic thrombocytopenia, or Shwachman-Diamond Syndrome)
Symptomatic paroxysmal nocturnal hemoglobinuria (PNH) and/or PNH clones >50% of polymorphonuclear neutrophil (PMN) or RBC at time of enrollment Myelodysplastic syndrome (MDS)
Any cytogenetic abnormalities on karyotyping or FISH within 30 days of study enrollment (an evaluable karyotyping with at least 10 metaphases is mandatory for eligibility)
Other known or suspected underlying primary immunodeficiency
Any concomitant malignancies that have not fully recovered from treatment or have not been disease-free for 5 years
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times the upper limit of normal (ULN)
Creatinine 2.5local ULN
Past medical history of thromboembolism within 6 months, and/or prior or current antiphospholipid antibody syndrome (APS)
Presence of clinically active uncontrolled significant (of such severity that it would preclude the subject's ability to consent, be compliant with study procedures, tolerate protocol therapy) infection, including bacterial, fungal, mycobacterial, parasitic or viral infection, or any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol
Any severe and/or uncontrolled medical conditions which could cause unacceptable safety risks or compromise compliance with the protocol, such as
Known hepatocellular disease (e.g. active hepatitis or cirrhosis)
Impairment of gastrointestinal (GI) function or gastrointestinal disease that may significantly alter the absorption of study treatment (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
Active skin, mucosa, ocular or GI disorders of Grade > 1
Presence of hepatitis B surface antigen (HBsAg) or positive hepatitis C antibody test result at screening. A positive serology for Hepatitis B (HB) is considered as a positive test for HBsAg. In addition, if serology is negative for HBsAg but hepatitis B core antibody (HBcAb) is positive (regardless of hepatitis B surface antibody (HBsAb) status), a hepatitis B virus (HBV) DNA test will be performed and if positive the patient will be excluded
Cardiac disorder (subjects with congestive heart disease of New York Heart Association (NYHA) functional classification Grade II/III/IV (for pediatric subjects, refer to the Grade II/III/IV of Modified ross heart failure classification for Children) should not be enrolled; subjects with NYHA Grade II due to cardiac disorder should not be enrolled but those with NYHA Grade II due to aplastic anemia (AA) may be enrolled.), arrhythmia with a risk of thrombosis (e.g. atrial fibrillation), pulmonary hypertension, or uncontrolled hypertension (>180/100 mmHg)
Other protocol-defined Inclusion/Exclusion may apply
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note